US 12,478,579 B2
Compressed nicotine lozenge
Dorthe Schackinger Boesen, Vejle (DK); Heidi Ziegler Bruun, Vejle Øst (DK); Bruno Provstgaard Nielsen, Vejle Øst (DK); Kent Albin Nielsen, Brande (DK); and Rikke Pranger-Rasmussen, Vejle (DK)
Assigned to Fertin Pharma A/S, Vejle (DK)
Filed by Fertin Pharma A/S, Vejle (DK)
Filed on Aug. 3, 2023, as Appl. No. 18/364,862.
Application 18/364,862 is a continuation of application No. 16/599,629, filed on Oct. 11, 2019, granted, now 11,759,419.
Prior Publication US 2024/0000706 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/465 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01)
CPC A61K 9/0056 (2013.01) [A61K 31/465 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01)] 18 Claims
 
1. A water-dissolvable compressed oral nicotine lozenge comprising a first module and a second module,
the first and the second modules being fused by compression,
the first and second modules being formed by a plurality of compressed particles,
the first module being a lozenge module comprising at least one sugar alcohol in an amount of at least 50% by weight of the first module, wherein the at least one sugar alcohol of the first module comprises at least one sugar alcohol selected from the group consisting of xylitol, maltitol, mannitol, erythritol, isomalt, sorbitol, lactitol and any combination thereof, and
the second module being a fast disintegrating tablet-module comprising at least one sugar alcohol in an amount of at least 50% by weight of the second module, superdisintegrant in an amount from 1 to 14% by weight of the second module, and nicotine, wherein the at least one sugar alcohol of the second module comprises at least one sugar alcohol selected from the group consisting of xylitol, maltitol, mannitol, erythritol, isomalt, sorbitol, lactitol and any combination thereof,
wherein the first module is free of nicotine, and
wherein the first module comprises flavor.